Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danlong Oral Liquid for AECOPD risk-window
ChiCTR2400087463Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Jul 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of Danlong in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: COPD Assessment Test at Week 12. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
Danlong
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2400087463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087463.